Cyclerion Therapeutics, Inc. (CYCN)
2025-03-31 | 2024-09-30 | |||
|---|---|---|---|---|
| Total revenues | 81 | 194 | ||
| Research and development | 36 | 81 | ||
| General and administrative | 1,502 | 1,241 | ||
| Total cost and expenses | 1,538 | 1,322 | ||
| Loss from operations | -1,457 | -723 | ||
| Interest income | - | 42 | ||
| Gain (loss) from settlement of account payable | - | 363 | ||
| Total other income, net | - | 405 | ||
| Net loss from continuing operations | - | -723 | ||
| Net gain (loss) | - | -723 | ||
| Basic eps | -0.56 | -0.29 | ||
| Diluted eps | -0.56 | -0.29 | ||
| Basic average shares | 2,556,000 | 2,526,000 | ||
| Diluted average shares | 2,556,000 | 2,526,000 | ||